A detailed history of Cwm, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Cwm, LLC holds 2,286 shares of LCTX stock, worth $1,234. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,286
Previous 1,643 39.14%
Holding current value
$1,234
Previous $2,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 08, 2024

BUY
$0.8 - $1.12 $514 - $720
643 Added 39.14%
2,286 $2,000
Q2 2024

Jul 09, 2024

BUY
$0.89 - $1.47 $115 - $191
130 Added 8.59%
1,643 $2,000
Q1 2024

Apr 05, 2024

BUY
$0.86 - $1.48 $1,301 - $2,239
1,513 New
1,513 $2,000
Q1 2022

Apr 21, 2022

SELL
$1.21 - $2.48 $42 - $86
-35 Closed
0 $0
Q4 2021

Jan 31, 2022

SELL
$1.84 - $2.68 $27,903 - $40,642
-15,165 Reduced 99.77%
35 $0
Q3 2019

Oct 22, 2019

BUY
$0.85 - $1.24 $12,920 - $18,848
15,200 New
15,200 $15,000

Others Institutions Holding LCTX

About Lineage Cell Therapeutics, Inc.


  • Ticker LCTX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 169,755,008
  • Market Cap $91.7M
  • Description
  • Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...
More about LCTX
Track This Portfolio

Track Cwm, LLC Portfolio

Follow Cwm, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.